《大行報告》瑞信上調財險(02328.HK)目標價至8.8元 評級「中性」
瑞信發表研究報告指,中國財險(02328.HK)日前發盈喜,預期首三季度淨利潤按年將增加約25%至30%,即第三季增長78%至108%,利潤增長強於市場預期。
該行指出,與壽險公司相比,由於投資槓桿較低,中國財險在A股市場的疲軟壓力可能較小,又指第三季保費收入增長加快,維持對2022財年總保費增長10%的預測,即第四季料按年增長9.3%。
該行估計,首九個月綜合成本率將按年提升2.3個百分點至96.6%,意味第三季料下降4.4個百分點至97.7%。瑞信將2022至2024財年每股盈利預測上調5%、3%及6%,目標價從8.6元上調至8.8元,評級維持「中性」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.